ClinicalTrials.gg
CompletedNCT02152007Updated Oct 7, 2016Results posted

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

A Phase 1 interventional study of 1% sirolimus cream (TD201 1%) in Pachyonychia Congenita, sponsored by TransDerm, Inc.. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-10-07.

Sponsored by TransDerm, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in adults with PC. Subjects may receive either placebo or treatment with at least 1 foot receiving topical sirolimus at some time. For certain phases of the study treatment assignment to the right and left foot will be randomized in a double blind fashion. Blood levels will test systemic absorption of sirolimus. Other safety and efficacy measures will be taken through the 39-week study duration. Funding Source - FDA OOPD

02

Conditions studied

  • Pachyonychia Congenita

Keywords

  • pachyonychia congenita
03

In context

Lead sponsor

This is the only study on the registry with TransDerm, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must:

  • Be capable of understanding the purpose and risks of the study and sign a written Form (ICF)
  • Be male or female ≥ 16 years of age at the time of the screening visit
  • Have a confirmed diagnosis of PC by genotyping (e.g., familial) and clinically correlated painful keratoderma.
  • Have roughly symmetrical calluses of similar severity on the plantar surface of both feet
  • Women of must have a negative serum pregnancy test
  • Subjects, whether male or female, with and who are sexually active must agree to use double-barrier methods

Exclusion criteria

Exclusion Criteria:

A Subject with any of the following criteria is not eligible for inclusion in this study:

  • Use of other drugs within 30 days of the screening visit and/or has not recovered from any side effects of prior investigational drugs or procedure in the affected area (e.g., a )
  • Significant condition in the dermatologic treatment area such as trauma, or nonhealing chronic wound
  • Pregnant or nursing (lactating) female, or a positive serum pregnancy test
  • Active infection either systemic or local near the site of treatment requiring chronic or prolonged use of antimicrobial agents
  • Known immunodeficiency including: Hepatitis A; ; ; (HIV)

Prior and Current Treatment

  • Unable to be discontinued from drugs known to either be inducers or inhibitors of /5 enzymes
  • Unable to be discontinued from drugs known to be P-glycoprotein inhibitors
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Split-body 1% sirolimus cream (TD201 1%)

    This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.

    Drug: 1% sirolimus cream (TD201 1%)

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels

    The primary outcome measure for this Phase 1b safety study is evaluation of system absorption through measurement of serum sirolimus trough levels. The limit of detection of the assay was 2.0 ng/mL.

    Time frame: Two weeks and every 1-2 months for 24 weeks or within 2 weeks after the last dose of study drug

Secondary outcomes

  1. Weekly Assessments Recorded in the PC Quality of Life Index

    Patient-reported weekly assessment in the PC Quality of Life Index

    Time frame: Weekly for 39 weeks

  2. Daily Assessments Recording in the PC Measurement Diary

    Time frame: Weekly for 39 weeks

Other outcomes

  1. Investigator Assessment of Local Tolerability

    Investigator assessment of local tolerability at the application sites on the plantar surfaces will be evaluated by the Investigator according to a 4-point scale (0, 1, 2, or 3; none to severe) with regard to: erythema, pruritis, stinging/burning, and crusting/erosion

    Time frame: Prior to application of study drug and within 15-45 minutes after application of study drug at each visit for 39 weeks

  2. Standardized Photographs

    An expert in the disease who is blinded to the study treatment will read the photographs of the callus area taken at each study visit. The reader will assess changes to the calluses based on criteria such as blisters, cracks, small/large size, and red or bloody spots on the callus. Change in calluses will be reported for both the right and left foot.

    Time frame: Each study visit over 39 weeks

07

Results

Posted Oct 7, 2016
Limitations and caveats
This study was primarily concerned with safety endpoints. Efficacy endpoints need to be improved for follow on studies.

Participant flow

Participant flow — Overall Study
MilestoneSplit-body 1% Sirolimus Cream (TD201 1%)
Started15
Completed14
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryEvaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels

The primary outcome measure for this Phase 1b safety study is evaluation of system absorption through measurement of serum sirolimus trough levels. The limit of detection of the assay was 2.0 ng/mL.

Time frame:
Two weeks and every 1-2 months for 24 weeks or within 2 weeks after the last dose of study drug
Reported as:
Number · participants
Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels
participantsSplit-body 1% Sirolimus Cream (TD201 1%)
Visit 1, Baseline, <2.0 ng/mL15
Visit 2, Week 3, <2 ng/mL15
Visit 3, Week 7, <2 ng/mL15
Visit 4, Week 13, <2 ng/mL14
Visit 5, Week 17, <2 ng/mL14
Visit 6, Week 25, <2 ng/mL14
Visit 7, Week 37, <2 ng/mL14
SecondaryWeekly Assessments Recorded in the PC Quality of Life Index

Patient-reported weekly assessment in the PC Quality of Life Index

Time frame:
Weekly for 39 weeks

Results for this outcome have not been posted.

SecondaryDaily Assessments Recording in the PC Measurement Diary
Time frame:
Weekly for 39 weeks

Results for this outcome have not been posted.

Other pre-specifiedInvestigator Assessment of Local Tolerability

Investigator assessment of local tolerability at the application sites on the plantar surfaces will be evaluated by the Investigator according to a 4-point scale (0, 1, 2, or 3; none to severe) with regard to: erythema, pruritis, stinging/burning, and crusting/erosion

Time frame:
Prior to application of study drug and within 15-45 minutes after application of study drug at each visit for 39 weeks
Reported as:
Mean · units on a scale
Investigator Assessment of Local Tolerability
units on a scaleSplit-body 1% Sirolimus Cream (TD201 1%)Placebo Cream (Vehicle Control)
Visit 1 Pre, Erythema Score (0-3)0.2 ± 0.410.2 ± 0.41
Visit 1 Pre, Pruritus Score (0-3)0.1 ± 0.260 ± 0
Visit 1 Pre, Stinging/Burning (0-3) Score0 ± 00.1 ± 0.26
Visit 1 Pre, Crusting/Erosion Score (0-3)0.1 ± 0.260.1 ± 0.26
Visit 1 Post, Erythema Score (0-3)0.2 ± 0.410.2 ± 0.41
Visit 1 Post, Pruritus Score (0-3)0 ± 00 ± 0
Visit 1 Post, Stinging/Burning Score (0-3)0 ± 00.1 ± 0.26
Visit 1 Post, Crusting/Erosion Score (0-3)0.1 ± 0.260.1 ± 0.26
Visit 4 Pre, Erythema Score (0-3)0 ± 00 ± 0
Visit 4 Pre, Pruritus Score (0-3)0.1 ± 0.280.1 ± 0.28
Visit 4 Pre, Stinging/Burning Score (0-3)0.1 ± 0.280 ± 0
Visit 4 Pre, Crusting/Erosion Score (0-3)0.1 ± 0.280.2 ± 0.38
Visit 4 Post, Erythema Score (0-3)0 ± 00 ± 0
Visit 4 Post, Pruritus Score (0-3)0 ± 00 ± 0
Visit 4 Post, Stinging/Burning Score (0-3)0.1 ± 0.280 ± 0
Visit 4 Post, Crusting/Erosion Score (0-3)0.1 ± 0.280.2 ± 0.38
Visit 7 Pre, Erythema Score (0-3)0.2 ± 0.580.2 ± 0.58
Visit 7 Pre, Pruritus Score (0-3)0.2 ± 0.580.2 ± 0.58
Visit 7 Pre, Stinging/Burning Score (0-3)0.3 ± 0.610.3 ± 0.61
Visit 7 Pre, Crusting/Erosion Score (0-3)0.4 ± 0.650.3 ± 0.61
Other pre-specifiedStandardized Photographs

An expert in the disease who is blinded to the study treatment will read the photographs of the callus area taken at each study visit. The reader will assess changes to the calluses based on criteria such as blisters, cracks, small/large size, and red or bloody spots on the callus. Change in calluses will be reported for both the right and left foot.

Time frame:
Each study visit over 39 weeks

Results for this outcome have not been posted.

Adverse events

Collected over Duration of the study, up to 39 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Split-body 1% Sirolimus Cream (TD201 1%)—0/15 (0%)6/15 (40%)
Most frequent other events
Most frequent other events
EventSplit-body 1% Sirolimus Cream (TD201 1%)
NauseaGastrointestinal disorders1/15
PyrexiaGeneral disorders1/15
Upper respiratory tract infectionInfections and infestations1/15
Musculoskeletal painMusculoskeletal and connective tissue disorders1/15
Dermatitis contactSkin and subcutaneous tissue disorders1/15
Skin ulcerSkin and subcutaneous tissue disorders1/15
UrticariaSkin and subcutaneous tissue disorders1/15
HeadacheNervous system disorders1/15
RhinorrheaRespiratory, thoracic and mediastinal disorders1/15

Baseline characteristics

This is a split-body design. After a 2-week run in phase in which both feet were treated with placebo, feet were randomized and one foot received 1% sirolimus and the other placebo ("randomized phase") for 8 weeks. Following the randomized phase, patients applied 1% sirolimus to both feet ("open label phase") for an additional 8 weeks.

Age, Categorical
Age, Categorical(Participants)Split-body 1% Sirolimus Cream (TD201 1%)
<=18 years0
Between 18 and 65 years15
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Split-body 1% Sirolimus Cream (TD201 1%)
Female9
Male6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Split-body 1% Sirolimus Cream (TD201 1%)
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White13
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Split-body 1% Sirolimus Cream (TD201 1%)
United States15
08

Study locations

1 site
  • Stanford University
    Stanford, California 94305, United States
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Jul 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2014
First posted
Jun 2, 2014
Start
Jan 2014
Primary completionActual
Jul 2015
CompletionActual
Nov 2015
Results first posted
Oct 7, 2016
Last update
Oct 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02152007
Lead sponsor
TransDerm, Inc.
Collaborators
Pachyonychia Congenita Project
Responsible party
Sponsor
First posted
Jun 2, 2014
Start date
Jan 2014
Primary completion
Jul 2015
Completion
Nov 2015
Results posted
Oct 7, 2016
Last update
Oct 7, 2016

Study contacts

Roger L Kaspar, PhD
study chair · TransDerm, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion